OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Julie Brahmer Explains the Role of PD-1 and PD-L1

September 13th 2013

Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, explains the role of PD-1 and PD-L1.

Dr. Steensma on ODAC's Pertuzumab Decision

September 12th 2013

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

Dr. Mok Discusses Developing Lung Cancer Treatments

September 12th 2013

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Suzanne Fuqua on the Interaction Between ER and AR

September 12th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine, Baylor College of Medicine, talks about the interaction between estrogen receptors (ER) and androgen receptors (AR) in patients with breast cancer.

Dr. Adjei on Adverse Events From MEK Inhibitors

September 11th 2013

Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses eye toxicity from MEK inhibitors.

Penny Daugherty on Discussing Patients' Genetics

September 11th 2013

Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, explains how nurses in her practice discuss genetics and genomics with patients.

Dr. Mitchell on Colorectal Cancer Treatment Options

September 10th 2013

Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, talks about the growing number of drugs and regimens for patients with colorectal cancer.

Dr. Gulley Discusses Vaccine Responses

September 10th 2013

James L. Gulley, MD, PhD, Head, Clinical Trials Group, Deputy Laboratory Chief, National Cancer Institute, discusses measuring response to vaccines.

Dr. Crawford Compares Degarelix and LHRH Agonists

September 9th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

Dr. Garcia on the Future Role of PARP inhibitors

September 9th 2013

Agustin A. Garcia, MD, associate professor of medicine, Keck School of Medicine of the University of Southern California, discusses the future role of PARP inhibitors for patients with ovarian cancer and breast cancer.

Dr. Finn on the Phase III Trial of Palbociclib for Breast Cancer

September 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Dr. Vogelzang Discusses the Prostate Health Cocktail

September 5th 2013

Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, describes the Prostate Health Cocktail.

Donna Berry on Patient Communication

September 5th 2013

Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, Associate Professor, Department of Medicine, Harvard Medical School, discusses using technology to communicate with patients

Dr. Brentjens on the Side Effects of CAR-Modified T Cells

September 4th 2013

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)â€“modified T cells when used to treat B-cell malignancies.

Dr. Sartor on Progress for the Treatment of Prostate Cancer

September 3rd 2013

A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.

Dr. Wakelee Discusses the AVAPERL Trial

August 30th 2013

Heather Wakelee, MD, an assistant professor at the Stanford University School of Medicine and member of the Stanford Cancer Institute, discusses the results of the AVAPERL trial.

Dr. Mittendorf on Cyclin E as a Target in Breast Cancer

August 29th 2013

Elizabeth Mittendorf, MD, PhD, Assistant Professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, discusses the potential to target cyclin E in breast cancer.

Dr. Vokes on HPV-Related Head and Neck Cancer

August 29th 2013

Everett E. Vokes, MD, Giant of Cancer Care in the Head and Neck Cancer Category, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses HPV-related head and neck cancer

Dr. Bradley on OX40 for the Treatment of Cancer

August 28th 2013

Edward Bradley, MD, from MedImmune (the global biologics research and development arm of AstraZeneca), describes the development of an agonist for the treatment of cancer.

Dr. Sosman on Immunotherapy in Melanoma and Renal Cancer

August 28th 2013

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.